Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.
about
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationCase studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in childrenPhysiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Dealing with the complex drug-drug interactions: towards mechanistic models.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways.Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants.Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
P2860
Q28088352-0D6130D5-2BA7-4D50-8F85-F1B2A13E3744Q30576914-C235B01A-71DD-4AA3-914A-77832F173961Q37279407-E30754CB-5689-4354-ADB5-A7845E4D7AFBQ38014312-E29D5BFE-02A9-4110-B012-ADC03BE534A9Q38050686-E8551127-FD73-4871-9337-687A4FE21642Q38087695-63CFEC0E-E4A8-43E1-993E-B404FEB67935Q38302225-A8D16AB1-2C05-464D-B048-E6FB5DF0756BQ38420688-10CB548E-4DA3-4D35-AF1B-8C7D24E0E9A0Q38458340-38A07695-75C8-4E0D-B9EE-C87DF3975E4AQ38844656-C9372EDB-47A3-4587-A2A7-3743A34A6F92Q39178447-82B219A4-E964-44E8-B1E4-024A3C4E04AFQ39240124-2A5DF69D-ADBC-428D-B831-6464904DBAF0Q39247285-EDA79400-744B-41D4-8BF7-C83B2401F4CAQ40829831-8A13B3FB-9B10-4DA0-BFEC-85191D38A75BQ41768726-585E5F05-1BC6-4132-90D2-CAF661D94A0DQ47134454-5A812E81-E62B-4ADD-B18E-A4FEAA96FA57Q47592224-682DE0C6-FBF2-43DD-9A17-809551B33559Q48076685-6F6C0286-FC74-4563-B65D-7ED9C1BDD3D7Q48333024-23027160-C967-4B50-A664-32CC19D7DF66Q51415497-7AD05228-1ABE-4963-ADDB-184703BD61E5Q52334679-E99FF129-4B60-496D-9610-8E8A096AB7F5
P2860
Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@en
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@nl
type
label
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@en
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@nl
prefLabel
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@en
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@nl
P2093
P2860
P356
P1476
Predicting drug interaction po ...... ime-dependent CYP3A inhibitor.
@en
P2093
E G Berglund
K S Reynolds
Md L T Vieira
P2860
P304
P356
10.1038/CLPT.2011.305
P407
P577
2012-03-07T00:00:00Z